Literature DB >> 22406268

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

Liang Shan1, Kai Deng, Neeta S Shroff, Christine M Durand, S Alireza Rabi, Hung-Chih Yang, Hao Zhang, Joseph B Margolick, Joel N Blankson, Robert F Siliciano.   

Abstract

Highly active antiretroviral therapy (HAART) suppresses HIV-1 replication but cannot eliminate the virus because HIV-1 establishes latent infection. Interruption of HAART leads to a rapid rebound of viremia, so life-long treatment is required. Efforts to purge the latent reservoir have focused on reactivating latent proviruses without inducing global T cell activation. However, the killing of the infected cells after virus reactivation, which is essential for elimination of the reservoir, has not been assessed. Here we show that after reversal of latency in an in vitro model, infected resting CD4(+) T cells survived despite viral cytopathic effects, even in the presence of autologous cytolytic T lymphocytes (CTLs) from most patients on HAART. Antigen-specific stimulation of patient CTLs led to efficient killing of infected cells. These results demonstrate that stimulating HIV-1-specific CTLs prior to reactivating latent HIV-1 may be essential for successful eradication efforts and should be considered in future clinical trials. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22406268      PMCID: PMC3501645          DOI: 10.1016/j.immuni.2012.01.014

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  60 in total

1.  Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

Authors:  Hans-Jürgen Stellbrink; Jan van Lunzen; Michael Westby; Eithne O'Sullivan; Claus Schneider; Axel Adam; Lutwin Weitner; Birger Kuhlmann; Christian Hoffmann; Stefan Fenske; Philipp S Aries; Olaf Degen; Christian Eggers; Heiko Petersen; Friedrich Haag; Heinz A Horst; Klaus Dalhoff; Christiane Möcklinghoff; Nick Cammack; Klara Tenner-Racz; Paul Racz
Journal:  AIDS       Date:  2002-07-26       Impact factor: 4.177

2.  No change to HIV-1 latency with valproate therapy.

Authors:  Alan Steel; Sally Clark; Ian Teo; Sunil Shaunak; Mark Nelson; Brian Gazzard; Peter Kelleher
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

3.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.

Authors:  T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

4.  HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.

Authors:  Albert Jordan; Dwayne Bisgrove; Eric Verdin
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

5.  Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue.

Authors:  Gilad Doitsh; Marielle Cavrois; Kara G Lassen; Orlando Zepeda; Zhiyuan Yang; Mario L Santiago; Andrew M Hebbeler; Warner C Greene
Journal:  Cell       Date:  2010-11-24       Impact factor: 41.582

6.  Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.

Authors:  T W Chun; D Engel; S B Mizell; C W Hallahan; M Fischette; S Park; R T Davey; M Dybul; J A Kovacs; J A Metcalf; J M Mican; M M Berrey; L Corey; H C Lane; A S Fauci
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

7.  Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

Authors:  Janet D Siliciano; Jun Lai; Marc Callender; Eleanor Pitt; Hao Zhang; Joseph B Margolick; Joel E Gallant; Joseph Cofrancesco; Richard D Moore; Stephen J Gange; Robert F Siliciano
Journal:  J Infect Dis       Date:  2007-01-30       Impact factor: 5.226

8.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

9.  Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control.

Authors:  Adam R Hersperger; Florencia Pereyra; Martha Nason; Korey Demers; Prameet Sheth; Lucy Y Shin; Colin M Kovacs; Benigno Rodriguez; Scott F Sieg; Leia Teixeira-Johnson; Debbie Gudonis; Paul A Goepfert; Michael M Lederman; Ian Frank; George Makedonas; Rupert Kaul; Bruce D Walker; Michael R Betts
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

10.  Granzyme B activity in target cells detects attack by cytotoxic lymphocytes.

Authors:  Beverly Z Packard; William G Telford; Akira Komoriya; Pierre A Henkart
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

View more
  443 in total

Review 1.  Eradication of human immunodeficiency virus from brain reservoirs.

Authors:  Avindra Nath
Journal:  J Neurovirol       Date:  2014-11-04       Impact factor: 2.643

2.  The future of HIV treatment.

Authors:  Martin S Hirsch; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

Review 3.  HIV-specific CD8⁺ T cells and HIV eradication.

Authors:  R Brad Jones; Bruce D Walker
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

4.  Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter.

Authors:  Haiyan Ji; Zhengtao Jiang; Panpan Lu; Li Ma; Chuan Li; Hanyu Pan; Zheng Fu; Xiying Qu; Pengfei Wang; Junxiao Deng; Xinyi Yang; Jianhua Wang; Huanzhang Zhu
Journal:  Mol Ther       Date:  2016-01-18       Impact factor: 11.454

5.  Viral latency and potential eradication of HIV-1.

Authors:  Kenneth A Matreyek; Ilker Oztop; Eric O Freed; Alan Engelman
Journal:  Expert Rev Anti Infect Ther       Date:  2012-08       Impact factor: 5.091

6.  Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity.

Authors:  Hiroyasu Ito; Tatsuya Ando; Kazuki Ando; Tetsuya Ishikawa; Kuniaki Saito; Hisataka Moriwaki; Mitsuru Seishima
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

7.  Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.

Authors:  Johannes Brozy; Erika Schlaepfer; Markus Muenz; Roberto F Speck; Christina K S Mueller; Mary-Aude Rochat; Silvana K Rampini; Renier Myburgh; Tobias Raum; Peter Kufer; Patrick A Baeuerle
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 8.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.

Authors:  Li Huang; Wei-Hong Lai; Lei Zhu; Wei Li; Lei Wei; Kuo-Hsiung Lee; Lan Xie; Chin-Ho Chen
Journal:  ACS Med Chem Lett       Date:  2018-02-06       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.